Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

InnoCare Pharma Presents Positive Phase II Results of ICP-488 in Psoriasis at AAD Meeting

Fineline Cube Mar 10, 2025

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the oral presentation of results from the...

Company

Nona Biosciences Launches Hu-mAtrIx: AI-Driven Engine for Accelerated Antibody Drug Discovery

Fineline Cube Mar 10, 2025

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced the introduction of...

Company Deals

Sichuan Biokin Pharmaceutical Plans RMB3.9 Billion Private Placement for Novel Drug R&D

Fineline Cube Mar 10, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced plans to raise up to RMB3.9...

Company Drug

LiteDD’s LIT0922 Approved for Phase I Trial in Marker-Expressing Advanced Solid Tumors

Fineline Cube Mar 10, 2025

The Center for Drug Evaluation (CDE) of China has approved LiteDD’s Category 1 product LIT0922...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4602 Clinical Study in Advanced Solid Tumors

Fineline Cube Mar 10, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical...

Company Medical Device

Jiangsu Cowin Biotech Obtains NMPA License for Gene Methylation Detection Kit

Fineline Cube Mar 10, 2025

China-based Jiangsu Cowin Biotech Co., Ltd. (SHA: 688426) announced receiving a Category III medical device...

Company Drug

InventisBio Announces Positive Phase II Results for D-2570 in Psoriasis Treatment

Fineline Cube Mar 10, 2025

China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) announced positive results from the Phase II study...

Company Drug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved by EU for Hepatocellular Carcinoma

Fineline Cube Mar 10, 2025

US giant Bristol-Myers Squibb (BMS, NYSE: BMY) announced receiving marketing approval from the European Commission...

Company Deals

Roche Launches Genentech Innovation Center in Boston to Accelerate Drug Development

Fineline Cube Mar 10, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the launch of the Roche Genentech Innovation...

Company Deals Medical Device

Sansure Biotech Plans RMB130 Million Investment in Shenzhen GeneMind for Gene Sequencing Expansion

Fineline Cube Mar 10, 2025

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced plans to invest RMB130 million...

Company Drug

AbbVie’s Skyrizi Approved by China’s NMPA for Moderate to Severe Crohn’s Disease

Fineline Cube Mar 10, 2025

US giant AbbVie (NYSE: ABBV) announced receiving marketing approval from China’s National Medical Products Administration...

Company Deals

Sun Pharma to Acquire Checkpoint Therapeutics for USD355 Million, Focusing on Cancer Immunotherapy

Fineline Cube Mar 10, 2025

India-based Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced plans to acquire all outstanding shares of...

Company Drug

Pfizer’s Elrexfio Receives Conditional NMPA Approval for Relapsed Multiple Myeloma

Fineline Cube Mar 10, 2025

US giant Pfizer (NYSE: PFE) announced receiving conditional approval from China’s National Medical Products Administration...

Company

MicroPort Scientific Corp. Reports 10% Revenue Growth and 58% Net Loss Decrease in 2024

Fineline Cube Mar 10, 2025

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) released its 2024 full-year performance estimation....

Company Medical Device

SonoScape Medical Corp. Wins First AI-Powered Prenatal Ultrasound Approval in China

Fineline Cube Mar 10, 2025

Shenzhen-based SonoScape Medical Corp. announced receiving marketing approval in China for its S-Fetus prenatal ultrasound...

Company Drug

TYK Medicines Inc.’s TY-9591 Shows Superiority Over Osimertinib in EGFR Mutated Lung Cancer with Brain Metastasis

Fineline Cube Mar 10, 2025

Zhejiang-based TYK Medicines Inc. (HKG: 2410) announced positive results from a pivotal Phase II study...

Company Deals

Anlong Biopharmaceutical and Sun-Novo Partner to Advance siRNA Technology in Cardiovascular Treatments

Fineline Cube Mar 10, 2025

On March 10, 2025, Anlong Biopharmaceutical and Sun-Novo Pharmaceutical announced a strategic partnership to advance...

Company Drug

AIM Vaccine Co. Ltd Receives NMPA Approval for Human Diploid Rabies Vaccine Trial

Fineline Cube Mar 10, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...

Company Deals

NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter

Fineline Cube Mar 9, 2025

NewCo is a new transaction model developed by Chinese innovative drug companies in response to...

Company

Hangzhou Chance Pharmaceuticals Secures New Funding for Inhalation Powder Aerosol Development

Fineline Cube Mar 9, 2025

Hangzhou Chance Pharmaceuticals recently announced the completion of a new funding round, led by Zhejiang’s...

Posts pagination

1 … 191 192 193 … 658

Recent updates

  • Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication
  • Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
  • WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion
  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication

Others

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

Company

WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.